CD4 and telomere syndrome: Keung et al. observed an increased proportion of CD4+ T cells and PD-L1 expression after preoperative irradiation.30 Another team reported a rise in the percentage of monocytes, M2 macrophages, B-cells, and CD4+ T cells after neoadjuvant therapy.31 A first non-comparative phase 2 trial report using neoadjuvant nivolumab and/or ipilimumab ± irradiation in localized STS (n = 27 patients given early trial closure).